Your session is about to expire
← Back to Search
VMD-928 for Advanced Cancer
Study Summary
This trial is testing a new drug for adults with advanced cancer that has not responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had chemotherapy that causes delayed side effects in the last 14 days.My cancer is not responding to standard treatments or has worsened after them.You need to have a sample of your tumor tissue available, or be willing to have a sample taken before starting the study, so that it can be tested for a specific protein called TrkA.I have a history of chronic hepatitis or liver cirrhosis due to any cause.My heart, liver, kidneys, or lungs are stable and won't affect my safety in the trial.My organs are working well.You have a negative result on a specific test called TrkA immunohistochemistry (IHC) assay.I haven't had cancer treatment like radiation or surgery in the last 2 weeks.I don't have severe side effects from past cancer treatments, except for hair loss or low blood count.I haven't had a heart attack or any heart procedures in the last 6 months.I am fully active or can carry out light work.Your heart's QTcF interval is longer than 480 milliseconds.My organs are functioning well.I do not have any mental health or personal issues that would stop me from following the study's requirements.I can take pills and keep them down.My organs are functioning well.I haven't taken any experimental cancer drugs within the last 14 days or 5 half-lives before starting VMD-928.My tumor shows high TrkA protein levels, has NTRK1 gene changes, or grew after Trk treatment.I do not have any active infections, including HIV.My heart condition significantly limits my physical activity.
- Group 1: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open slots for prospective participants in this research?
"Correct. Clinicaltrials.gov reports that this medical experiment is currently recruiting participants, with the original posting taking place on June 8th 2018 and the most recent update made to it on September 28th 2022."
Has the FDA endorsed VMD-928 300 mg Tablets or 100 mg Capsules?
"The safety of VMD-928 300 mg Tablets or 100 mg Capsules is estimated as a 1 due to its Phase 1 classification, signifying that there are only early signs of efficacy and minimal data supporting safety."
How many sites are currently implementing this research endeavor?
"The University of Texas MD Anderson Cancer Center in Houston, Medical College of Wisconsin located in Milwaukee, and Weill-Cornell Medicine at Cornell University are the most notable medical sites that this clinical trial is running out of. This along with 7 other locations across the US make up the entire list."
Share this study with friends
Copy Link
Messenger